Masitinib (colored in red) binds and inhibits the activity of LYN (pink), FYN (blue) and BLK (yellow). Credit: E. Oricchio/EPFL
The efficacy of target specific therapies in lymphoma is limited to subgroups of patients. EPFL scientists have identified a mechanism that confers resistance against a common therapy for lymphoma. They propose an alternative treatment that targets lymphoma signaling at its root, and show that it can be effective in a broader group of patients. The study is published in the journal Blood. Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes or B cells. Like cells in all cancers, the B cells begin to grow out of control, creating tumors in the lymph nodes, spleen or other tissues. In 2010 alone, it was estimated that non-Hodgkin lymphomas caused 210,000 deaths worldwide.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
